About m7GpppN-mRNA hydrolase
m7GpppN-mRNA hydrolase (DCP2) is a protein
from Homo sapiens identified by UniProt accession
Q8IU60, 420 residues long.
MolForge cross-references it against 0 known binders and
74 disease associations.
Target properties
| Protein name | m7GpppN-mRNA hydrolase |
|---|
| UniProt accession | Q8IU60 |
|---|
| Gene | DCP2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 420 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (74)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.54
- lysosomal storage disease · score 0.37
- reticulocyte count · score 0.30
- reticulocyte measurement · score 0.23
- body height · score 0.22
- hypertension · score 0.22
- self reported educational attainment · score 0.20
- total blood protein measurement · score 0.16
- sex hormone-binding globulin measurement · score 0.15
- diastolic blood pressure · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8IU60-F1 | alphafold | PREDICTED | 66.81 | — |
Amino-acid sequence (420 residues)
METKRVEIPG SVLDDLCSRF ILHIPSEERD NAIRVCFQIE LAHWFYLDFY MQNTPGLPQC GIRDFAKAVF SHCPFLLPQG EDVEKVLDEW KEYKMGVPTY GAIILDETLE NVLLVQGYLA KSGWGFPKGK VNKEEAPHDC AAREVFEETG FDIKDYICKD DYIELRINDQ LARLYIIPGI PKDTKFNPKT RREIRNIEWF SIEKLPCHRN DMTPKSKLGL APNKFFMAIP FIRPLRDWLS RRFGDSSDSD NGFSSTGSTP AKPTVEKLSR TKFRHSQQLF PDGSPGDQWV KHRQPLQQKP YNNHSEMSDL LKGKNQSMRG NGRKQYQDSP NQKKRTNGLQ PAKQQNSLMK CEKKLHPRKL QDNFETDAVY DLPSSSEDQL LEHAEGQPVA CNGHCKFPFS SRAFLSFKFD HNAIMKILDL
Explore m7GpppN-mRNA hydrolase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets